fashion -WSS

fashion

author：comprehensive 2025-09-05 18:31:35 - browse：361

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： How medical schools plan to diversify without affirmative action

focus

WSS

Food makers tried to stack nutrition panel with preferred experts

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Walmart eyes Medicare Advantage provider ChenMed

UnitedHealth, Optum discontinue NaviHealth name

ADCs take center stage as promising cancer treatments

entertainment

fashion

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Cancer drug shortages should be causing more outrage

Cassava Sciences’ Alzheimer’s clinical trials should be halted

In age of alternative facts, a scholarly course on calling out crap

WATCH: Why do bright lights make us see spots?

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast: Live from the 2023 STAT Summit

Hepatitis C has a cure — but many Americans still lack access to it

ADCs take center stage as promising cancer treatments

knowledge

FDA proposes changes to key medical devices approval pathway

Why a market frenzy over new weight loss drugs defies logic

Food makers to regulators: Ultra

Will the IRA bring competition to the biologics market?

STAT Readout Newsletter: Biotech news today

FDA proposes changes to key medical devices approval pathway

hotspot

focus

entertainment

focus